Ocular Therapeutix is making changes to its senior leadership team, according to a press release.
Peter K. Kaiser, MD, will join the company in the newly created role of chief medical advisor, retina. He will be tasked with advising on clinical development strategies for the company’s retina programs, including OTX-TKI, which is in phase 1 development for the treatment of wet age-related macular degeneration and other retinal diseases. He also will continue to serve as Chaney Family Endowed Chair in Ophthalmology Research and professor of ophthalmology at the Cleveland Clinic (Read more...)